Literature DB >> 18417516

Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension.

S Provencher1, P Hervé, O Sitbon, M Humbert, G Simonneau, D Chemla.   

Abstract

Improvement in exercise capacity may not be associated with significant changes in resting pulmonary haemodynamics. The present prospective study documented the relationships between improvement in 6-min walking distance (6MWD) and changes in resting and exercise pulmonary haemodynamics after treatment in patients with idiopathic pulmonary arterial hypertension (IPAH). A total of 42 IPAH patients underwent supine submaximal exercise haemodynamic assessments at baseline and after 5+/-2 months of therapy. The 6MWD, the corresponding chronotropic response (peak minus resting heart rate), and resting and exercise haemodynamic variables were analysed. The isoflow was defined as the lowest of the pre- and post-treatment peak cardiac index (CI). The extrapolated isoflow mean pulmonary artery pressure ((pa)) was used to characterise changes in (pa)-CI regression lines following treatment. Patients were given bosentan (n = 28), epoprostenol (n = 12) or both. The 6MWD increased significantly, from 399+/-88 to 442+/-86 m. On univariate analysis, changes in 6MWD correlated with changes in isoflow (pa), chronotropic response, resting haemodynamics (CI, pulmonary vascular resistance and mixed venous oxygen saturation) and exercise haemodynamics (peak CI). On multivariate analysis, only changes in isoflow (pa) and chronotropic response were independently associated with changes in 6MWD. Improvement in exercise tolerance with chronic therapy is independently related to improvement in pulmonary haemodynamics measured in exercise but not in resting conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417516     DOI: 10.1183/09031936.00009008

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  17 in total

1.  Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

Authors:  Rajeev Saggar; Dinesh Khanna; Daniel E Furst; Shelley Shapiro; Paul Maranian; John A Belperio; Neeraj Chauhan; Philip Clements; Alan Gorn; S Sam Weigt; David Ross; Joseph P Lynch; Rajan Saggar
Journal:  Arthritis Rheum       Date:  2010-12

2.  Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Authors:  Soundos Saleh; Corina Becker; Reiner Frey; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

3.  Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.

Authors:  Adriano R Tonelli; Laith Alkukhun; Vineesha Arelli; José Ramos; Jennie Newman; Kevin McCarthy; Bohdan Pichurko; Omar A Minai; Raed A Dweik
Journal:  Clin Transl Sci       Date:  2013-09-06       Impact factor: 4.689

4.  RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study.

Authors:  Susana Hoette; Nicolas Creuzé; Sven Günther; David Montani; Laurent Savale; Xavier Jaïs; Florence Parent; Olivier Sitbon; Carlos Eduardo Rochitte; Gerald Simonneau; Marc Humbert; Rogerio Souza; Denis Chemla
Journal:  Lung       Date:  2018-02-12       Impact factor: 2.584

Review 5.  Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Authors:  Nils P Nickel; Ke Yuan; Peter Dorfmuller; Steeve Provencher; Yen-Chun Lai; Sebastien Bonnet; Eric D Austin; Carl D Koch; Alison Morris; Frédéric Perros; David Montani; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

Review 6.  A review of exercise pulmonary hypertension in systemic sclerosis.

Authors:  Faisal Shaikh; Zafia Anklesaria; Tasneam Shagroni; Rajeev Saggar; Luna Gargani; Eduardo Bossone; Michael Ryan; Richard Channick; Rajan Saggar
Journal:  J Scleroderma Relat Disord       Date:  2019-06-14

7.  Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension.

Authors:  Konstadina Darsaklis; Matthew E Dickson; William Cornwell; Colby R Ayers; Fernando Torres; Kelly M Chin; Susan Matulevicius
Journal:  Int J Cardiovasc Imaging       Date:  2016-04-13       Impact factor: 2.357

8.  Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency.

Authors:  Gerrina Ruiter; Emmy Manders; Chris M Happé; Ingrid Schalij; Herman Groepenhoff; Luke S Howard; Martin R Wilkins; Harm J Bogaard; Nico Westerhof; Willem J van der Laarse; Frances S de Man; Anton Vonk-Noordegraaf
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 9.  High Right Ventricular Afterload during Exercise in Patients with Pulmonary Arterial Hypertension.

Authors:  Mari Nishizaki; Aiko Ogawa; Hiromi Matsubara
Journal:  J Clin Med       Date:  2021-05-09       Impact factor: 4.241

10.  Pim-1: A new biomarker in pulmonary arterial hypertension.

Authors:  Sébastien Renard; Roxane Paulin; Sandra Breuils-Bonnet; Serge Simard; Philippe Pibarot; Sébastien Bonnet; Steeve Provencher
Journal:  Pulm Circ       Date:  2013-01       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.